在接受心脏手术的儿科患者中使用血管活性 - 诺托普药物:单中心回顾性研究
Yan-Ting Sun1,2, Li-Hong Wang2,3, Yun-Tai Yao2
1Department of Anesthesiology, Baoji high-tech Hospital, Shaanxi, China.
Medicine
|May 5, 2025
概括
密利诺,多巴胺和多布胺是最常见的血管活性 - 异位热剂在儿科心脏手术中使用. 它们的使用因麻醉师和手术类型而异,突出显示了不同的药物实践.
科学领域:
- 儿童心脏病学 儿童心脏病学
- 麻醉学 麻醉学
- 药理学 药理学是指药理学的学科.
背景情况:
- 血管活性 - - 诺托普剂在儿科心脏外科手术中对血液动力学管理至关重要.
- 了解当前的使用模式对于优化患者护理和制定临床指南至关重要.
研究的目的:
- 为了回顾性地分析小儿心脏手术患者的血管活性 - 诺托普剂的利用情况.
- 识别常见的药物,它们的应用时间,以及医疗保健提供者之间以及不同手术风险类别的使用差异.
主要方法:
- 福威医院对401名儿科心脏手术患者的回顾性审查 (2021年4月至6月).
- 在手术期间和儿科重症监护室 (PICU) 期间使用血管活性 - 诺托普剂的分析.
- 根据患者年龄,心脏手术风险调整1 (RACHS-1) 类别和麻醉师的药物使用分层.
主要成果:
- 米利诺 (81.6%),多巴胺 (68.3%) 和多布他胺 (65.4%) 是最常用于手术期间的内类药物.
- 术后第一天 (3.9%) 在PICU中使用压素的比例最高.
- 毫里诺,多巴胺和多布他胺的组合是常见的,在提供者之间使用情况有显著差异,在RACHS-1类别4手术中使用率更高.
结论:
- 米利诺,多巴胺和多布胺是福威医院儿科心脏手术中主要的血管活性-内托洛普剂.
- 麻醉科医生在药物选择和组合策略方面存在显著的变化.
- 通过RACHS-1类别表示的外科复杂性,影响了选择血管活性-无热支持的选择.
相关概念视频
Heart Failure Drugs: Inotropic Agents
440
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
440
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.1K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.1K
Heart Failure Drugs: β-Blockers
284
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
284
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
665
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
665
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
846
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
846
Depolarizing Blockers: Pharmocokinetics
296
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
296


